1887
Volume 2022, Issue 4
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Introduction: Patients with multiple comorbidities who have coronavirus disease 2019 (COVID-19) have high morbidity and mortality. Glucose-6-phosphate dehydrogenase (G6PD) deficiency has been shown to have an enhanced effect on coronavirus in an earlier study.

Methods: We conducted this comparative observational study to evaluate the effects of COVID-19 disease on G6PD deficiency based on the hematologic parameters, COVID-19-related hospitalizations, and mortality in the state of Qatar between January 2020 and May 2020 at four designated COVID-19 facilities. We identified 41 patients with G6PD deficiency who had documented COVID-19 infection. We compared the results with 241 patients with COVID-19 infection who tested negative for G6PD deficiency Results: Comparing the COVID-19 positive G6PD deficient with COVID-19 positive G6PD normal activity showed that G6PD normal group had higher white blood cell count (WBC), absolute neutrophil count (ANC), lymphocytes, eosinophils, and monocytes counts versus the G6PD deficient group ( < 0.001).

Conclusions: When compared with COVID-19 patients with normal G6PD, patients with COVID-19 infection and G6PD deficiency had lower total WBC, ANC, lymphocyte, monocyte, and eosinophil counts. However, no evidence of increased hemolysis, thrombosis, morbidity, or mortality was observed in COVID-19 patients with G6PD deficiency

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2022.54
2022-11-16
2022-12-03
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2022/4/qmj.2022.54.html?itemId=/content/journals/10.5339/qmj.2022.54&mimeType=html&fmt=ahah

References

  1. Live C. Coronavirus Statistics Worldometer [Internet] 2022 [Available from: https://www.worldometers.info/coronavirus.
    [Google Scholar]
  2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al.. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382:(8):727–33.
    [Google Scholar]
  3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:(10223):497–506.
    [Google Scholar]
  4. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al.. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020; 395:(10239):1763–70.
    [Google Scholar]
  5. De Sanctis V. Prevalence, Clinical Manifestations, and Biochemical Data of Hypertensive versus Normotensive Symptomatic Patients with COVID-19: A Comparative Study. Acta Biomed. 2020; 91:(4):e2020164.
    [Google Scholar]
  6. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020; 80:(6):e14–e8.
    [Google Scholar]
  7. Soliman AT, Prabhakaran Nair A, Al Masalamani MS, De Sanctis V, Abu Khattab MA, Alsaud AE, et al.. Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study. Acta Biomed. 2020; 91:(3):e2020010.
    [Google Scholar]
  8. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al.. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020; 92:(10):1875–83.
    [Google Scholar]
  9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395:(10229):1054–62.
    [Google Scholar]
  10. De Sanctis V, Bedair EMA, Soliman AT, Nair AP, Al Masalamani MA, Yassin M. Proposed Scoring System for Evaluating Clinico-radiological Severity of COVID- 19 using Plain Chest X- ray (CXR) changes (CO X-RADS): Preliminary results. Acta Biomed. 2020; 91:(4):e2020172.
    [Google Scholar]
  11. Wei C, Liu Y, Liu Y, Zhang K, Su D, Zhong M, et al.. Clinical characteristics and manifestations in older patients with COVID-19. BMC Geriatr. 2020; 20:(1):395.
    [Google Scholar]
  12. Al-Abdi S, Al-Aamri M. G6PD deficiency in the COVID-19 pandemic: Ghost within Ghost. Hematol Oncol Stem Cell Ther. 2021; 14:(1):84–5.
    [Google Scholar]
  13. Youssef JG, Zahiruddin F, Youssef G, Padmanabhan S, Ensor J, Pingali SR, et al.. G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg? Ann Hematol. 2021; 100:(3):667–73.
    [Google Scholar]
  14. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008; 371:(9606):64–74.
    [Google Scholar]
  15. Alharbi KK, Khan IA. Prevalence of glucose-6-phosphate dehydrogenase deficiency and the role of the A- variant in a Saudi population. J Int Med Res. 2014; 42:(5):1161–7.
    [Google Scholar]
  16. Doss CG, Alasmar DR, Bux RI, Sneha P, Bakhsh FD, Al-Azwani I, et al.. Genetic Epidemiology of Glucose-6-Phosphate Dehydrogenase Deficiency in the Arab World. Sci Rep. 2016;6:37284.
    [Google Scholar]
  17. Usanga EA, Ameen R. Glucose-6-phosphate dehydrogenase deficiency in Kuwait, Syria, Egypt, Iran, Jordan and Lebanon. Hum Hered. 2000; 50:(3):158–61.
    [Google Scholar]
  18. Buinitskaya Y, Gurinovich R, Wlodaver CG, Kastsiuchenka S. Centrality of G6PD in COVID-19: The Biochemical Rationale and Clinical Implications. Front Med (Lausanne). 2020;7:584112.
    [Google Scholar]
  19. Wu YH, Tseng CP, Cheng ML, Ho HY, Shih SR, Chiu DT. Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. J Infect Dis. 2008; 197:(6):812–6.
    [Google Scholar]
  20. Afra TP, Nampoothiri RV, Razmi TM, Hafi NAB. Linking hydroxychloroquine to hemolysis in a ’suspected’ glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal. Eur J Intern Med. 2020;80:101–2.
    [Google Scholar]
  21. Aguilar J, Averbukh Y. Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report. Perm J. 2020;24.
    [Google Scholar]
  22. Chaney S, Basirat A, McDermott R, Keenan N, Moloney E. COVID-19 and hydroxychloroquine side-effects: glucose 6-phosphate dehydrogenase deficiency (G6PD) and acute haemolytic anaemia. Qjm. 2020; 113:(12):890–1.
    [Google Scholar]
  23. Mastroianni F, Colombie V, Claes G, Gilles A, Vandergheynst F, Place S. Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander? Eur J Case Rep Intern Med. 2020; 7:(9):001875.
    [Google Scholar]
  24. Khneisser I, Farra C. Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19. J Med Screen. 2021; 28:(1):54.
    [Google Scholar]
  25. Son K-B, Lee T-j, Hwang S-s. Disease severity classification and COVID-19 outcomes, Republic of Korea. Bulletin of the World Health Organization. 2021; 99:(1):62–6.
    [Google Scholar]
  26. Yang HC, Ma TH, Tjong WY, Stern A, Chiu DT. G6PD deficiency, redox homeostasis, and viral infections: implications for SARS-CoV-2 (COVID-19). Free Radic Res. 2021; 55:(4):364–74.
    [Google Scholar]
  27. Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005; 72:(7):1277–82.
    [Google Scholar]
  28. Longo L, Vanegas OC, Patel M, Rosti V, Li H, Waka J, et al.. Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. Embo j. 2002; 21:(16):4229–39.
    [Google Scholar]
  29. Ong KIC, Kosugi H, Thoeun S, Araki H, Thandar MM, Iwagami M, et al.. Systematic review of the clinical manifestations of glucose-6-phosphate dehydrogenase deficiency in the Greater Mekong Subregion: implications for malaria elimination and beyond. BMJ Glob Health. 2017; 2:(3):e000415.
    [Google Scholar]
  30. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al.. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012; 9:(11):e1001339.
    [Google Scholar]
  31. Alwazeer D, Liu FF-C, Wu XY, LeBaron TW. Combating Oxidative Stress and Inflammation in COVID-19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives. Oxidative Medicine and Cellular Longevity. 2021;2021:5513868.
    [Google Scholar]
  32. Chao YC, Huang CS, Lee CN, Chang SY, King CC, Kao CL. Higher infection of dengue virus serotype 2 in human monocytes of patients with G6PD deficiency. PLoS One. 2008; 3:(2):e1557.
    [Google Scholar]
  33. Ho HY, Cheng ML, Weng SF, Chang L, Yeh TT, Shih SR, et al.. Glucose-6-phosphate dehydrogenase deficiency enhances enterovirus 71 infection. J Gen Virol. 2008; 89:(Pt 9):2080–9.
    [Google Scholar]
  34. Wu YH, Chiu DT, Lin HR, Tang HY, Cheng ML, Ho HY. Glucose-6-Phosphate Dehydrogenase Enhances Antiviral Response through Downregulation of NADPH Sensor HSCARG and Upregulation of NF-κB Signaling. Viruses. 2015; 7:(12):6689–706.
    [Google Scholar]
  35. Aydemir D, Dağlıoğlu G, Candevir A, Kurtaran B, Bozdogan ST, Inal TC, et al.. COVID-19 may enhance risk of thrombosis and hemolysis in the G6PD deficient patients. Nucleosides Nucleotides Nucleic Acids. 2021; 40:(5):505–17.
    [Google Scholar]
  36. Mohamed MFH, Al-Shokri SD, Shunnar KM, Mohamed SF, Najim MS, Ibrahim SI, et al.. Prevalence of Venous Thromboembolism in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2020;7:598846.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2022.54
Loading
/content/journals/10.5339/qmj.2022.54
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): absolute neutrophil countCOVID-19G6PDSARS-CoV-2 and white blood cells
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error